Abstract
The rapidly expanding knowledge of the pathogenesis of a variety of forms of cancer at the molecular level is now providing new targets for drug discovery and development. This has enabled us to successfully develop rationally designed therapies for cancer patients, and the results of their clinical evaluation are now becoming available. The optimal clinical development of target-based anticancer drugs will require fundamental changes to the way trials are designed, outcome is evaluated, and patients are selected to receive therapy. A thorough knowledge of what is accomplished so far is the cornerstone to optimally develop and implement these new strategies.
Keywords: targeted therapy, egfr, her2, vegfr
Current Cancer Therapy Reviews
Title: Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer
Volume: 1 Issue: 1
Author(s): Antonio Jimeno and Hernán Cortes-Funes
Affiliation:
Keywords: targeted therapy, egfr, her2, vegfr
Abstract: The rapidly expanding knowledge of the pathogenesis of a variety of forms of cancer at the molecular level is now providing new targets for drug discovery and development. This has enabled us to successfully develop rationally designed therapies for cancer patients, and the results of their clinical evaluation are now becoming available. The optimal clinical development of target-based anticancer drugs will require fundamental changes to the way trials are designed, outcome is evaluated, and patients are selected to receive therapy. A thorough knowledge of what is accomplished so far is the cornerstone to optimally develop and implement these new strategies.
Export Options
About this article
Cite this article as:
Jimeno Antonio and Cortes-Funes Hernán, Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer, Current Cancer Therapy Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573394052952519
DOI https://dx.doi.org/10.2174/1573394052952519 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Hypertension, Antihypertensive Therapy and Renal-Cell Cancer: A Meta-Analysis
Current Drug Safety Preface
Current Pharmaceutical Design Caffeine Effect on HIFs/VEGF Pathway in Human Glioblastoma Cells Exposed to Hypoxia
Anti-Cancer Agents in Medicinal Chemistry COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry A Key Role for Altered Dendritic Cell Functioning in the Impaired Immunity Seen in Aged Individuals
Current Immunology Reviews (Discontinued) An In Silico Immunogenicity Analysis for PbHRH: An Antiangiogenic Peptibody by Fusing HRH Peptide and Human IgG1 Fc Fragment
Current Bioinformatics Deciphering the Novel Target Genes Involved in the Epigenetics of Hepatocellular Carcinoma Using Graph Theory Approach
Current Genomics Melanogenesis Inhibitors: Strategies for Searching for and Evaluation of Active Compounds
Current Medicinal Chemistry The Orvinols and Related Opioids - High Affinity Ligands with Diverse Efficacy Profiles
Current Pharmaceutical Design Current Status of Anti-Tuberculosis Therapy: A Patent Analysis
Recent Patents on Anti-Infective Drug Discovery Magnetic Resonance Elastography
Current Medical Imaging Similar and Shared Nongenomic Mechanisms of Action of Estrogen and Thyroid Hormone
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Two-Domain Vascular Disruptive Agents in Cancer Therapy
Current Cancer Drug Targets MicroRNA-21 as a Novel Therapeutic Target
Current Cancer Therapy Reviews Using a Machine-Learning Approach to Predict Discontinuous Antibody-Specific B-Cell Epitopes
Current Bioinformatics Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry MDM2 Inhibitors for Pancreatic Cancer Therapy
Mini-Reviews in Medicinal Chemistry